References
- Dretler AW, Rouphael NG, Stephens DS. Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development. Hum Vaccin Immunother. 2018;15:1–35. doi:10.1080/21645515.2018.1451810.
- Yüksel S, Evrengül H, Özçakar ZB, Becerir T, Yalçın N, Korkmaz E, Ozaltin F. First-line, early and long-term eculizumab therapy in atypical hemolytic uremic syndrome: a case series in pediatric patients. Paediatr Drugs. 2016;18(6):413–20. doi:10.1007/s40272-016-0194-0.
- McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morbidity and mortality weekly report 2017;66:734–7.